clinical trial · NCT05017298
Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells
Corona Virus InfectionCovid19Allogeneic adipose-derived stem cells
brief summary
This is an interventional new drug clinical trial for a Phase 2 randomized, double-blind, and placebo control study using intravenous injection of allogeneic adipose stem cells (Celltex AdMSCs) for subjects with severe COVID-19.
started
Nov 1, 2024
primary completion
Nov 1, 2024
completion
Nov 15, 2026
last updated
Feb 7, 2024
official title
Clinical Study for Subjects With Coronavirus 2019 (COVID-19) Using Multiple Dose Intravenous Infusions of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol